508 related articles for article (PubMed ID: 28320716)
21. Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.
Papp-Wallace KM; Barnes MD; Alsop J; Taracila MA; Bethel CR; Becka SA; van Duin D; Kreiswirth BN; Kaye KS; Bonomo RA
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610205
[TBL] [Abstract][Full Text] [Related]
22.
Karlowsky JA; Lob SH; DeRyke CA; Hilbert DW; Wong MT; Young K; Siddiqui F; Motyl MR; Sahm DF
Antimicrob Agents Chemother; 2022 May; 66(5):e0018922. PubMed ID: 35491836
[TBL] [Abstract][Full Text] [Related]
23. Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018-2020.
Hilbert DW; DeRyke CA; Motyl M; Hackel M; Young K
BMC Microbiol; 2023 Jun; 23(1):165. PubMed ID: 37312049
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.
Karlowsky JA; Lob SH; Siddiqui F; Pavia J; DeRyke CA; Young K; Motyl MR; Sahm DF
Braz J Infect Dis; 2023; 27(3):102775. PubMed ID: 37169345
[TBL] [Abstract][Full Text] [Related]
25. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.
Young K; Painter RE; Raghoobar SL; Hairston NN; Racine F; Wisniewski D; Balibar CJ; Villafania A; Zhang R; Sahm DF; Blizzard T; Murgolo N; Hammond ML; Motyl MR
BMC Microbiol; 2019 Jul; 19(1):150. PubMed ID: 31272373
[TBL] [Abstract][Full Text] [Related]
26. Clonal Background, Resistance Gene Profile, and Porin Gene Mutations Modulate
Gomez-Simmonds A; Stump S; Giddins MJ; Annavajhala MK; Uhlemann AC
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891602
[TBL] [Abstract][Full Text] [Related]
27. Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan.
Yang TY; Hsieh YJ; Kao LT; Liu GH; Lian SH; Wang LC; Lin IL; Wang HY; Tseng SP; Lu PL
J Microbiol Immunol Infect; 2022 Feb; 55(1):86-94. PubMed ID: 33678555
[TBL] [Abstract][Full Text] [Related]
28. Activity of imipenem/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018-2019.
Lob SH; Hackel MA; Young K; Motyl MR; Sahm DF
Diagn Microbiol Infect Dis; 2021 Aug; 100(4):115421. PubMed ID: 34082265
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
30.
Kurihara D; Matsumoto S; Kishi N; Ishii Y; Mori M
Microbiol Spectr; 2022 Apr; 10(2):e0223521. PubMed ID: 35416695
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019.
Walkty A; Karlowsky JA; Baxter MR; Adam HJ; Golden A; Lagace-Wiens P; Zhanel GG;
Diagn Microbiol Infect Dis; 2021 Sep; 101(1):115418. PubMed ID: 34102373
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.
Karlowsky JA; Lob SH; Chen WT; DeRyke CA; Siddiqui F; Young K; Motyl MR; Sahm DF
Int J Antimicrob Agents; 2023 Sep; 62(3):106900. PubMed ID: 37354921
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant gram-negative pathogens.
Xu C; Chen T; Zhang S; Zhou C; Liao W; Fang R; Chen L; Zhou T
Diagn Microbiol Infect Dis; 2022 Jul; 103(3):115712. PubMed ID: 35613493
[TBL] [Abstract][Full Text] [Related]
34.
Asempa TE; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262769
[TBL] [Abstract][Full Text] [Related]
35.
Schmidt-Malan SM; Mishra AJ; Mushtaq A; Brinkman CL; Patel R
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760145
[TBL] [Abstract][Full Text] [Related]
36. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
[TBL] [Abstract][Full Text] [Related]
37. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202
[TBL] [Abstract][Full Text] [Related]
38. Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013-2015.
Karlowsky JA; Hoban DJ; Hackel MA; Lob SH; Sahm DF
Braz J Infect Dis; 2017; 21(3):343-348. PubMed ID: 28399424
[TBL] [Abstract][Full Text] [Related]
39. Imipenem-Relebactam Susceptibility in
Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
[TBL] [Abstract][Full Text] [Related]
40. Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae.
Canver MC; Satlin MJ; Westblade LF; Kreiswirth BN; Chen L; Robertson A; Fauntleroy K; La Spina M; Callan K; Jenkins SG
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
